ARTICLE | Product Development
Phagelux: new life in lysins
CEO Mark Engel narrows the focus of his cross-border biotech to first- and best-in-class skin products and phage-based platform technologies.
January 8, 2022 3:14 AM UTC
A year-end out-licensing deal for a Staphylococcus lysin has brought serial entrepreneur Mark Engel’s Phagelux a large Chinese partner with regulatory and commercial chops as the start-up looks to raise its next round of capital to advance its lysins, phages and affiliated technologies.
As viruses that selectively kill bacteria and can be combined into targeted, updatable cocktails, phages and the lysin proteins they produce have long been considered a counter to the downsides of broad-spectrum antibiotics. ...